Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 23, 2024 3:31pm

92 Views

Post# 36102415

RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

ONCY presented biomarker pancreatic cancer data at AACR 2019 found the following, before going on in May 2024 to demonstrate pelareorep's ability to expand TiL in both the blood and tumor cells.

"Using patient blood samples from our REO 024 study in second line pancreatic cancer, T cell receptor sequencing was performed with Adaptive Biotechnologies' immunoSEQ Assay to measure the diversity or clonality of the T cell population,'' said Dr. Rita Laeufle, CMO of Oncolytics Biotech. ''Results from this analysis demonstrate that higher clonality after one three-week cycle of treatment can identify patients likely to respond to combination treatment of pelareorep and a checkpoint inhibitor.''

https://www.accesswire.com/537346/Oncolytics-BiotechR-Presents-Biomarker-Data-in-Second-line-Pancreatic-Cancer-at-AACR

In May 2024 ONCY further elaborated on pelareorep's ability to expand TiL in both the blood and tumor cell highlightes pelareorep's MOA and potential as a backbone immunotherapy for multiple cancer indications.

“Pelareorep stimulates a proinflammatory response that primes tumors for immunologic killing and also activates both innate and adaptive immune responses. Our second ASCO abstract provides additional support for pelareorep’s immunotherapeutic mechanism of action by describing its ability to stimulate the expansion of pre-existing and new TIL clones in the blood, which correlate with treatment response. These results build upon previously reported data from the AWARE-1 study in breast cancer to expand our understanding of pelareorep’s immune-based mechanism of action, and it supports further investigation of TIL expansion as a potential biomarker of clinical activity in patients treated with pelareorep.”

https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-asco-abstracts-highlight-pelareoreps-potential-in-pancreatic-cancer-and-immunotherapeutic-mechanism-of-action/

"Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. "

https://oncolyticsbiotech.com/press_releases/oncolytics-provides-update-on-pancreatic-cancer-program-for-pelareorep/

As also posted in May 2024 - " In recent years, the global cancer biologics market has witnessed several notable trends that have reshaped its dynamics:

Rise of Targeted Therapies: Targeted therapies have emerged as a significant driver of demand in the global cancer biologics market. These therapies, designed to specifically interfere with the molecular and genetic pathways driving cancer growth, have revolutionized oncology treatment by offering enhanced efficacy and reduced side effects.
Precision Medicine Revolution: Targeted therapies are at the forefront of the precision medicine revolution in oncology. Through the identification of specific genetic mutations and biomarkers, oncologists can tailor treatment regimens to individual patients, leading to more effective outcomes.
Advancements in Oncolytic Viruses and NGS Technologies: Oncolytic viruses and next-generation sequencing (NGS) technologies have deepened our understanding of the genetic underpinnings of cancer. This has paved the way for personalized medicine strategies, wherein treatments are customized based on the unique genetic profiles of patients.
Liquid Biopsies: Liquid biopsies have emerged as a less intrusive alternative to conventional tissue biopsies. These tests enable the monitoring of treatment efficacy, identification of minimal residual disease, and pinpointing of mechanisms of resistance, thereby facilitating more informed treatment decisions."